RGLS vs. ALIM, LXRX, AGEN, VNDA, EBS, XOMA, CDXS, ACHV, RIGL, and SGMO
Should you be buying Regulus Therapeutics stock or one of its competitors? The main competitors of Regulus Therapeutics include Alimera Sciences (ALIM), Lexicon Pharmaceuticals (LXRX), Agenus (AGEN), Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), XOMA (XOMA), Codexis (CDXS), Achieve Life Sciences (ACHV), Rigel Pharmaceuticals (RIGL), and Sangamo Therapeutics (SGMO). These companies are all part of the "medical" sector.
Regulus Therapeutics (NASDAQ:RGLS) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, community ranking, risk and analyst recommendations.
92.4% of Regulus Therapeutics shares are held by institutional investors. Comparatively, 99.8% of Alimera Sciences shares are held by institutional investors. 4.4% of Regulus Therapeutics shares are held by company insiders. Comparatively, 31.4% of Alimera Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Regulus Therapeutics had 1 more articles in the media than Alimera Sciences. MarketBeat recorded 2 mentions for Regulus Therapeutics and 1 mentions for Alimera Sciences. Regulus Therapeutics' average media sentiment score of 0.00 equaled Alimera Sciences'average media sentiment score.
Regulus Therapeutics received 125 more outperform votes than Alimera Sciences when rated by MarketBeat users. Likewise, 63.54% of users gave Regulus Therapeutics an outperform vote while only 57.70% of users gave Alimera Sciences an outperform vote.
Regulus Therapeutics presently has a consensus target price of $7.25, suggesting a potential upside of 197.13%. Alimera Sciences has a consensus target price of $8.00, suggesting a potential upside of 166.67%. Given Regulus Therapeutics' higher possible upside, analysts clearly believe Regulus Therapeutics is more favorable than Alimera Sciences.
Regulus Therapeutics has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.
Alimera Sciences has higher revenue and earnings than Regulus Therapeutics. Alimera Sciences is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Regulus Therapeutics has a net margin of 0.00% compared to Alimera Sciences' net margin of -23.74%. Alimera Sciences' return on equity of -53.49% beat Regulus Therapeutics' return on equity.
Summary
Regulus Therapeutics beats Alimera Sciences on 9 of the 16 factors compared between the two stocks.
Get Regulus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RGLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regulus Therapeutics Competitors List
Related Companies and Tools
